Friday, October 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· May 15, 2026

Axe Compute Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

View original at globenewswire.com
“The Company held $6.9 million in cash and cash equivalents... as of March 31, 2026.”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The $260 million GPU cluster will go live in Q3 2026, translating to approximately $21 million per quarter in revenue.

    60% confidence
  • Global AI spending is forecast to reach $2.52 trillion in 2026, a 44% increase year-over-year.

    60% confidence
  • Axe Compute's pipeline now exceeds $4 billion and the goal of closing $1 billion in new customer agreements by end of 2026 seems to be very much within reach.

    60% confidence
  • Approximately $6.7 trillion is projected to be spent on data centers globally between 2025 and 2030, of which approximately 65.7% is GPU-related.

    60% confidence
  • The Company's combined liquidity position of approximately $36.5 million is sufficient to fund operations through fiscal 2026 and beyond.

    60% confidence
  • The $4.3 million non-cash mark-to-market loss on ATH digital asset holdings in Q1 2026 was tied directly to the decline in the market price of the Aethir token during Q1.

    60% confidence
  • Q1 2026 marked the beginning of contracts for the compute business, and the April $260 million contract is the clearest signal yet of what the platform can deliver.

    60% confidence
  • As of early 2026, average GPU procurement lead times stand at 36 to 52 weeks, creating a durable commercial opportunity for Axe Compute's distributed, enterprise-first GPU compute model.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com